ANGPTL3 and metabolic dysfunction-associated steatotic liver disease: The ob/ob mice, vaccinated with a peptide targeting ANGPTL3, also exhibited a marked decrease in diet-induced obesity and hepatic steatosis [111], suggestive of the metabolic impact of ANGPTL3 on NAFLD.